Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced positive results from the KRYSTAL-1 study for KRAZATI in combination with cetuximab, showing significant efficacy in treating KRASG12C-mutated colorectal cancer. The study, funded by Mirati Therapeutics, a Bristol Myers Squibb company, will be presented at the AACR annual meeting. The FDA has accepted a supplemental new drug application for this combination, with a PDUFA goal date of June 21, 2024.
April 08, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's KRAZATI, in combination with cetuximab, shows promising results for colorectal cancer treatment, with FDA priority review underway.
The positive results from the KRYSTAL-1 study and the FDA's acceptance of a supplemental new drug application for KRAZATI in combination with cetuximab indicate a strong potential for market impact. The priority review status suggests a high level of confidence in the treatment's efficacy and safety, potentially leading to a significant positive impact on Bristol Myers Squibb's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100